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Re-irradiation of painful bony metastases is increasingly performed since patients are receiving better
systemic treatments and having longer life expectancy, and may also be due to the increase use of
initial single fraction radiotherapy. However, randomized control trial on the efﬁcacy of re-irradiation is
lacking. A recent meta-analysis concluded with a 58% response rate for pain relief by re-irradiation of
symptomatic bone metastases. In this review, the effectiveness of re-irradiation in terms of clinical and
economical aspects, and clinical questions on who, when, and how to re-irradiate would be discussed.
A brief review of other treatment options and comparison with re-irradiation of bone metastases would
be performed.
& 2013 Elsevier GmbH. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Re-irradiation of symptomatic recurrent painful bone
metastases
Radiotherapy to painful bony metastases is undoubtedly use-
ful in pain relief. It was demonstrated on a recent updated
systemic review [1] that the effectiveness in pain relief is
comparable for single-fraction (SF) and multi-fraction (MF) radio-
therapy. It was found that 11–42% and 0–24% of patients given SF
and MF treatment respectively would eventually require retreat-
ment [2]. The re-irradiation rate is signiﬁcantly higher in patients
with single fraction radiotherapy (2.6 fold, 20% versus 9% in the SF
arm versus the MF arm respectively) [1]. On the other hand, with
increased effectiveness of systemic cancer treatment, patients
nowadays have longer life expectancy. Thus, bone re-irradiation is
increasingly considered. A recent systematic review and meta-
analysis by Huisman et al. [3] included 2694 patients treated with
re-irradiation from 4 Gy up to 26 Gy, 2–8 Gy per fraction daily.
It showed an overall pain response of 58%.
Toxicities are the major concern for re-irradiation. Huisman
et al. [3] reviewed the toxicities from various studies, and reported
that toxicity data was only available in three studies from Jeremic. This is an open access article un
ology, Odette Cancer Centre,
Avenue, Toronto, Ontario,
16 480 6002.et al. in 1999 [4]and 2002 [5], and van der Linden et al. in 2004 [6]
respectively. Jeremic et al. 1999 [4] reported that there was no
serious acute toxicity (ZRTOG grade 3). Pathological fractures
were reported in 3/135 (2%) patients and spinal cord compression
in 3/135 (2%) patients.. The main side effect was mainly gastro-
intestinal (grade 1 or 2 nausea and vomiting) in 18% (25/135). The
same group in 2002 [5] reported there was no acute or late high-
grade toxicity (43), no pathological fractures or spinal cord
compression. Van den Linden et al. [6] reported retreatment
toxicities in both single-fraction (SF) versus multi-fraction (MF)
treatment groups with Rotterdam Symptom Checklist. Most SF and
MF patients reported no or only mild nausea and vomiting. Nausea
score 4 (very bad) was reported in 12% of MF patients vs. 6% of SF
patients (p¼0.39). Vomiting score 4 (very bad) was reported in
1 MF patient and 2 SF patients (p¼0.49). Severe tiredness was
reported in 18% of SF patients and 27% of MF patients (p¼0.41).
Overall, it seems that re-irradiation is a tolerable treatment.
Cost effectiveness is another major concern for the govern-
ments in countries with public health system. Van-den Hout WB
et al. at Netherlands [7] did a cost utility analysis showing the
cost of radiation treatment including re-treatment for bone
metastases using SF versus MF were h2438 versus h3311 respec-
tively. RTOG 9714 groups showed the expected mean cost was
US $1009 and US $2322 for treating with 8 Gy/1 Fr and 30 Gy/
10 Fr respectively [8]. It is evident that SF is more cost effective
than MF treatment. Physicians are therefore advised to consider
more single fractioned radiotherapy on uncomplicated boneder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Even taking into account of higher re-treatment rate using initial
SF radiotherapy, the cost is still lower than performing initial SF
and retreatment with MF radiotherapy [7].
In palliative medicine, maintaining the quality of life (QOL) is
the most important goal of both patients and palliative physicians.
However, there is no trial addressing the QOL of patient receiving
re-irradiation for their painful bone metastases. The development
of EORTC-QLQ BM22 [9] would probably standardize the outcomes
on QOL in upcoming trials, and hopefully, we will have a better
idea on how re-irradiation improves the QOL of patients in
quantitative means. A simpliﬁed treatment plan would deﬁnitely
help in improving the QOL of patient. Successful re-irradiation to
painful bony sites may potentially minimize the use of analgesics.
Thus, patients would deﬁnitely beneﬁt in terms of improving
their QOL.2. Re-irradiation of other organs
Re-irradiation of other body sites is increasingly attempted by
physicians worldwide. However, randomized control trials are again
lacking. The response rate of re-irradiating each site varies. Table 1
shows a comparison of response rate of re-irradiating different
organs.
Late toxicities are challenging for physicians. Tissue tolerance
of various organs had been discussed by Nieder et al. [10] in 2000.
Having said that toxicities were observed after exceeding a
certain cumulative dose at BED at 2 Gy, oncologists often try
their best to stretch the maximal tolerance of major organs by
using better dose painting technique to minimize dose to organs
at risk, and at the same time giving the best local control with
irradiation. Dose constraints of the brain stem and brain tolerance
in re-treatment of head and neck cancer recurrences were well
documented on RTOG 9610 and 9911 protocols, though long term
results of complications are awaited. Comparing re-irradiating
organs with painful bone metastases especially non-axial bones,
there is much less concern for late complications of bones.3. Alternatives in treating bone pain recurrence
Huisman et al. [3] suggested physicians to explore more on other
sorts of treatment including radionuclides and bone targeting
therapy. It is therefore worthwhile to understand more on the
response rate and cost effective of other alternatives in comparison
with that of re-irradiation of bone metastases.Table 1
Re-irradiation in different body parts
Organ/ Trials First RT
fractionation/dosage
Second R
Brain Akiba T et al. 2012 [29] N¼31 30 Gy/10 Fr 3-4 Gy/1
Brain Sadikov E et al. 2007 [30] N¼72 20 Gy/5 Fr 15–25 Gy
Brain Hazuka MB et al. 1988 [31] N¼44 30–36 Gy (at 1.5–
4.0 Gy/fraction)
6–36 Gy
Head & Neck Review by Mendenhall et al. 2008 [32]





Spinal Cord Maranzano et al. 2011 [33] N¼24 8–16 Gy/1–2 Fr 4–20 Gy,
Lung Critical review by Jeremic et al. 2011 [34]
N¼307
30–78 Gy 4–60 Gy
n NPC: nasopharyngeal carcinoma.3.1. Analgesics
Pain management with oral analgesics is usually conducted
according to World Health Organization (WHO) analgesic ladder,
and it provides adequate pain control in 80–90% of patient [11].
Cost of oral analgesics varies. The cost of commonly used analge-
sics such as acetaminophen, NSAID, codeine, tramadol and mor-
phine sirup is usually low with less than $15 US dollars per day. It
is more costly for fentanyl patches in cases of difﬁcult pain control
(A 100-microgram patch of fentanyl costs between $60 and $75 US
dollars). However, the side effects of analgesics will cause con-
siderable nuisance to patients’ QOL. Common side effects of opioid
drugs include nausea and vomiting, constipation and dry mouth.
Signiﬁcant side effects of NSAIDs include risk of peptic ulcer and
bleeding. The quality of life is greatly jeopardized by complicated
schedule of analgesics and their side effects, especially in elderly
patients having co-morbidities already given multiple medica-
tions. Therefore, it is desirable to minimize analgesics. Moreover,
mechanical pain and breakthrough pain are often difﬁcult to
control with regular analgesics. Thus, many patients prefer to
minimize mobilization if they suffer from mechanical bone pain,
which subsequently lead to debilitation and other undesired
complications such as bed sores, chest infection and depression.
These patients may need localized treatment, for example, radio-
therapy, surgery or nerve blocks for controlling baseline pain.
3.2. Bone modifying agents
Bisphosphonates have been widely used in the past decade.
It was shown to be effective in reducing skeletal related events
(SREs) in breast cancer using zoledronic acid by 41% compared with
placebo [12], by 11% in prostate cancer [13]. FDA approved its
indications in reducing hypercalcaemia in malignancy, in multiple
myelomas, and in bone metastases of solid tumors [14]. In terms of
pain relief, marked pain relief (deﬁned as a two-point decrease
lasting for o¼6 weeks) was reported by Conte et al. [15] in 44% of
pamidronate patients and in 30% of controls in breast cancer
patients with bone metastases (p¼0.025). Wheinfurt et al. [16]
reported that patients receiving zoledronic acid had a 33% chance of
a favorable pain relief, compared with 25% for patients receiving
placebo in prostate cancers with bone metastases (p¼0.04; 95% CI
0.5%–15.6%). A meta-analysis conducted by Wong et al. [17]
reviewing 30 randomized control trials concluded with favorable
likelihood of pain relief and analgesic reduction at week 4 and week
12. Bisphosphonates are undoubtedly useful for multiple painful
bony sites beyond localized treatment. However, side effects includ-
ing renal toxicity, osteonecrosis of jaw (ONJ), and hypocalcaemia are
well known. The mean time to occurrence of ONJ was found to be
1.8 years after the most potent bisphosphonate zoledronic acid [18].
Therefore, many physicians are cautious for its long term use. ForT fractionation/ dosage Response rate
–20 Fr 68% (symptomatic improvement) 55% tumor RR
, 2–3 Gy per fraction 31%
at 2.0–4.0 Gy/fraction 27% neurological improvement
h brachytherapy or SRS.
ies Non-NPC
(local control) NPC:47-89% Second relapse: 33% Non-
NPC: 4–81% loco-regional control
3–8 Gy per fraction 85.7% in ambulant patients 0% in non-ambulant
patients
48–81% (symptom improvement)
F. Mok et al. / Journal of Bone Oncology 2 (2013) 33–37 35pain recurrence after completing a course of bisphosphonate, other
alternatives have to be considered.
A novel fully human monoclonal antibody, denosumab, seems
to be a promising bone modifying agent. It inhibits the matura-
tion of osteoclasts by binding to and inhibiting RANKL. Cleeland
et al. [19] reported its superior outcome in alleviating pain, and
also a statistically signiﬁcant 4-month delay in progression to
moderate to severe pain in patient with no or mild pain at
baseline with denosumab compared with zoledronic acid. A
meta-analysis published in similar period by Sun et al. [20]
reviewed seven reports from three randomized controlled trials
involving 5723 patients and showed that denosumab signiﬁcantly
delayed time to ﬁrst on-study SRE [hazard ratio (HR)¼0.83; 95%
CI, 0.76-0.90, Po0.001], time to multiple SRE (HR¼0.83; 95% CI,
0.76–0.90, Po0.001), and pain worsening (HR¼0.92; 95% CI,
0.86-0.99, p¼0.026) for patients with bone metastases compared
with zoledronic acid, yet similar result in pain improvement.
It was approved by FDA for increasing bone mass in patients at
high risk for fracture including androgen deprivation therapy
(ADT) for non-metastatic prostate cancer or adjuvant aromatase
inhibitor (AI) therapy for breast cancer [21].
In terms of cost effectiveness, Cartel et al. [22] reported that
cost of denosumab and zoledronic acid including drug, adminis-
tration and monitoring to be US $25,016 and $15,994 per patient
respectively. The cost per quality-adjusted life year (QALY) gained
was US $644,000. There was an incremental cost/quality-adjusted
life year (QALY) gained 4US $600,000 by denosumab, which is
far higher than what is considered to be good value for a medical
intervention ($50,000–$100,000/QALY). Overall, both zoledronic
acid and denusomab are expensive. Patients with multiple sites of
complicated bone metastases would beneﬁt from both. However,
re-irradiation of isolated painful uncomplicated bony sites would
be much more cost effective.3.3. Optimizing systemic treatment
Optimizing systemic treatment may improve symptoms
including bone pain and also perhaps improve progression free
survival and overall survival. Various new chemotherapy, tar-
geted agents and hormonal therapy are available. Response rates
of frequently used systemic treatment in the three commonest
cancers are shown on Table 2. However, the patient should be ﬁt
to receive such systemic treatment as it will also cause signiﬁcant
side effects affecting the patient’s quality of life. In addition, the
cost of chemotherapy and new targeted agents remain to be a
huge burden to the government and also patients especially in
countries that patients need to pay for their own drugs. Verg-
nenegre et al. [23] reported the cost of docetaxel and pemetrexed
in second line treatment of metastatic non-small cell lung cancer
were h97097h6272 and h13,4367h6508 respectively. The cost-
utility was h32,652/quality-adjusted life year for docetaxel and
h40,980/quality-adjusted life year for pemetrexed respectively.Table 2
Response rates of commonly used ﬁrst line and second line systemic therapy
Organ/Systemic treatment Response rate of 1st line treatment
Breast Chemotherapy 42%–72% [35–38] (Docetaxel) 73% (FAC) [39]
Breast Hormone 30% (Letrozole) 20% (Tamoxifen) [43]





64% (OxaliplatinþCetuximab) [48]It is again considerably more costly than delivering palliative
radiotherapy treatment. Taking non-small cell lung cancer treat-
ment as an example, even with low response rate and high cost of
second line chemotherapy, it is still widely prescribed in meta-
static cancer patients for its potential survival beneﬁt.4. Re-irradiation of bone metastases is efﬁcacious
Overall, re-irradiation of bone metastases is much less costly,
having high response rate and low toxicities compared with other
alternatives. It is deﬁnitely worthwhile to consider re-irradiation in
uncomplicated isolated bone metastases having pain recurrence.
More understanding on ‘who’, ‘when’ and ‘how’ to re-irradiate bone
metastases would be important.5. Who, when and how to re-irradiate recurrent painful bone
metastases
‘Who’ would likely respond to re-treatment? Jeremic et al. [4]
conducted a prospective trial with 4 Gy in one fraction after initial
4 Gy single fraction treatment with a response rate of 74%. Those
who initially had a complete response were more likely to achieve
another complete response then those with partial response
(p¼0.042), and those with initial partial response were also more
likely to achieve another partial response (p¼0.00054). Even for
non-responders, 46% did have a partial or complete response with
re-irradiation. Jeremic et al. [5] later conducted another study on
25 patients who receive 4Gy in one fraction after given single
fraction radiotherapy (4, 6, or 8 Gy plus 4 Gy) for twice, suggested
a response rate of 84%, and 67% in previous responders and non –
responders respectively. It seems that both initial responders and
non- responders would beneﬁt from re-irradiation for one or more
times. Van den Linden et al. [6] reported that the pain score before
retreatment signiﬁcantly predicted retreatment (Po0.001). Retreat-
ment for non-responders was successful in 66% SF vs. 33% MF
patients (p¼0.13), and retreatment for progression was successful
in 70% SF vs. 57% MF patients (p¼0.24). However, with the back-
ground that SF is as effective as MF treatment in terms of pain
response [1], SF is encouraged to be implemented as ﬁrst line
treatment in uncomplicated bone metastases, thus higher response
rate of re-treatment may be anticipated in subsequent trials. Overall,
it seems that no matter SF or MF treatment was initially given and
whether patients responded initially, those presented with recurrence
of bone pain would deﬁnitely worth being considered for re-
irradiation. Those who responded initially may beneﬁt more.
On the other hand, it was also shown that multi-fraction long-
course radiotherapy results in better re-calciﬁcation and fewer
recurrences of spinal cord compression within the irradiated spinal
region [24,25]. In case of recurrence, Nieder et al. [10] reviewed
that re-irradiation of the spinal cord to a cumulative biological
equivalent dose (BED) of 130 to 135 Gy2 was safe when the initialResponse rate of 2nd line treatment
42% (retry Docetaxel) [40] 30% (Gemcitabine/Vinorelbine) [41] 30%
(Capecitabine) [42]
30.7% (ExemestaneþGnRH agonist in pre-menopausal women) [44] 14.3%
(Fulvestrant) [45]
e/ 12% (Docetaxel) [47]
10.8% (FOLFIRI) 22.9% (FOLIFIRIþCetuximab) [49]
F. Mok et al. / Journal of Bone Oncology 2 (2013) 33–3736dose did not exceed 90 Gy2. Therefore, for patients with spinal
cord compression or who are at risk of spinal cord compression, a
more protracted initial course of radiotherapy is recommended in
order to avoid unsalvageable recurrence and complicated calcula-
tion during retreatment in patients with good performance status.
‘When’ to give re-irradiation? It is also generally recom-
mended to consider re-irradiation after at least 4 weeks in
patients not responding to initial radiation [26], and deﬁnitely
at the time when pain recurs. When organs at risk are in-ﬁeld of
re-treatment portal, tissue tolerance has to be taken into con-
sideration. However, as the time for recovery is still unknown,
exact tolerance of organs at risk during retreatment is uncertain
and more studies are warranted in this aspect.
‘How’ to give re-irradiation? Jeremic et al. [4] found that there
was no difference in efﬁcacy for 4, 6 or 8 Gy in single fraction after
an initial 4 Gy single-fraction treatment. Mithal et al. [27] reported
the outcomes of 105 patients with 57 out of 280 individual painful
sites retreated. The pain response was 87%, in which 74% [17–23]
responded with SF treatment and 91% [31–34] responded with MF
treatment. The number of patients was small to draw a conclusion
if MF was superior compared with SF treatment for re-irradiation.
However, in cases when organs at risk are in ﬁeld, careful
calculation to tissue tolerance for the dose fractionation has to be
taken into account.
The most optimal situations and the best way to give re-
irradiation to bone metastases are still unknown. The results of an
ongoing study phase III study NCIC CTG SC20 [28] should be able
to answer more on ‘how’ to deliver re-irradiation. The study
included patients with initial radiation dose to the extremities/
ribs/ pelvis with either single or multi-fractionation and only
excluded patients with initial dose of 24 Gy in 6 fractions, 27 Gy
in 8 fractions or 30 Gy in 10 fractions to the spine or any part of
the pelvis encompassing small or large bowel and/or the rectum.6. Conclusion
Re-irradiation for uncomplicated painful bony sites is highly
recommended for its high response rate, favorable toxicity proﬁle
and low cost compared with other types of treatment. It also
potentially decreases the use of analgesics. Patients’ quality of life
would certainly be improved. Results of SC 20 are awaited in order
to know more on the most optimal way to conduct re-irradiation.Acknowledgments
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